Evidence map›Paper›PMID 39802731›Full record

ArticleCase reports in women's health2025

Low-dose naltrexone as a treatment for vulvodynia: A case series.

Renee T Sullender, R Gina Silverstein, Diamond M Goodwin, Asha B McClurg, Erin T Carey

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renee T SullenderDivision of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.
R Gina SilversteinDivision of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.
Diamond M GoodwinDivision of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.
Asha B McClurgDivision of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.
Erin T CareyDivision of Minimally Invasive Gynecology Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 460 Waterstone Drive, Hillsborough, NC 27278, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vulvodynia is a chronic vulvar pain condition that can be challenging to treat and often requires multi-modal interventions for symptom management. Low-dose naltrexone (LDN) is a reversible competitive antagonist at opioid receptors and may have utility in treating chronic pain conditions. In a specialty gynecology clinic at an academic medical center, patients with poorly controlled vulvodynia who had failed standard treatments were offered LDN as an adjunct pain treatment. This case series describes the experience of three patients with chronic vulvodynia who added LDN to their treatment regimen. All patients reported subjective improvement in their symptoms without side-effects. Additional research is needed on the efficacy of LDN for chronic pelvic pain conditions such as vulvodynia as well as the long-term safety profile of such use.

Indexed as

Chronic pelvic painDyspareuniaLow-dose naltrexoneVulvar painVulvodynia

Identifiers

PMID39802731
PMCPMC11719202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.